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Children with hyperdiploid but not triple trisomy (14,110,117) acute
lymphoblastic leukemia have an increased incidence of extramedullary
relapse on current therapies: A single institution experience
Anjali Sharathkumar,1 Deborah DeCamillo,2 Kanta Bhambhani,2,3 Barbara Cushing,2,3 Ronald Thomas,4
Anwar N. Mohamed,5 Yaddanapudi Ravindranath,2,3 and Jeffrey W. Taub2,3*
To evaluate the outcome of children with high hyperdiploid acute lymphoblastic leukemia (hHDALL) treated
at the author’s institution. One hundred thirty-five consecutive children with B-precursor ALL were diag-
nosed between 1991 and 2002: 38 (28.1%) hHDALL and 97 (71.9%) non-hHDALL. In the hHDALL group, 11/
38 (28.9%) relapsed at a median interval of 2.8 years (range: 0.8–5.0 years) with 9/11 relapses occurring at
the end or after the completion of therapy. Three (27.3%) relapses were isolated hematopoietic (BM), while
eight (72.7%) were either isolated extramedullary (EM) relapses (n 5 6; Testis: 4; CNS: 2) or combined he-
matopoietic and extramedullary relapses (n 5 2; BM 1 CNS: 1; BM 1 Testis: 1). For the non-hHDALL group,
29/97 (29.9%) relapsed. Unlike the hHDALL group, the non-hHDALL group experienced hematopoietic relap-
ses (62%; n 5 18) more frequently than isolated extramedullary (27.5%; n 5 8: Testis: 1; CNS: 7) or com-
bined hematopoietic and extramedullary relapses (10.3%; CNS 1 BM: 3), with 24/29 (82.8%) of the relapses
occurring on therapy. Relapses in hHDALL frequently involved EM sites (P 5 0.053). Presence of triple tris-
omy of 14,110,117 at diagnosis had a protective effect against relapse (P < 0.05). Five-year EFS for the
hHDALL and non-hHDALL patients was similar, 70.5 ± 7.5% and 66.4 ± 4.9%, respectively. Five-year OS for
the hHDALL patients was significantly higher than for the non-hHDALL patients, 92 ± 4.5% vs. 74.1 ± 4.5%,
P 5 0.038. Biologically significant differences exist between relapse patterns of hHDALL and non-hHDALL
cases related to relapse sites and time periods when relapses occur. hDALL relapses continue to be
chemo-sensitive. Am. J. Hematol. 83:34–40, 2008. VC 2007 Wiley-Liss, Inc.
Introduction
Identification of recurring chromosomal abnormalities
including ploidy has a major impact on risk assignment for
treatment of childhood acute lymphoblastic leukemia (ALL)
[1–6]. Among the distinguishing cytogenetic features of
acute lymphoblastic leukemia (ALL), a high hyperdiploid
karyotype with a modal chromosome number (MCN) of 51–
65 chromosomes is one of the most reliable predictors of a
favorable clinical outcome [1–6]. It is present in 25% of
pediatric B-precursor ALL cases [2–6] and 85% of chil-
dren with this form of ALL can be cured with contemporary
treatments [1]. High hyperdiploid ALL (hHDALL) can also
be identified by the DNA content of blast cells measured by
flow cytometry as the DNA index (DI). The most common
chromosomes present in extra copy number in hHDALL are
21, 6, X, 14, 4, 18, 17, 10, 8, and 5 [7–10]. Patients within
the hHDALL category typically have several favorable prog-
nostic features at diagnosis including: (i) age between 2
and 10 years, (ii) low initial white blood cell count, and (iii)
expression of the stem cell marker (CD34) in addition to
common ALL antigen (cALLA) expression.
In this article, we report our institutional experience of
treating a cohort of children with hHDALL with an emphasis
on their relapse patterns compared with non-hHDALL
cases. We observed that the relapse pattern of hHDALL is
different than the other subsets of childhood ALL with a
predisposition to extramedullary relapse sites.
Results
From January 1991 to December 2002, 135 children
(age > 1 year to 18 years) were diagnosed with B-precur-
sor ALL at Children’s Hospital of Michigan (CHM). A total
of 38 children had hHDALL (MCN 51–65 chromosomes).
Thus, the hHDALL group constituted 38 (28.1%) and the
non-HD group included the remaining 97 (71.9%) children.
Median follow-up for the entire cohort was 7.6 years
(range: 1.2 months to 15.2 years). Descriptive demographic
features of both the groups are shown in Tables I and II.
Relapse characteristics of high hyperdiploid ALL
Eleven of 38 patients in the hHDALL group (28.9%; 95%
CI: 13.72–42.17) experienced a leukemia relapse (Tables I
and II) at a median interval from diagnosis to relapse of 2.8
years (range: 0.8–5.0 years). Two (18%) relapses occurred
prior to therapy completion at week 39 (UPN 29) and week
1Department of Pediatrics and Communicable Diseases, C.S. Mott Child-
ren’s Hospital, University of Michigan, Ann Arbor, Michigan; 2Division of He-
matology/Oncology, Children’s Hospital of Michigan, Michigan; 3Department
of Pediatrics, Wayne State University School of Medicine, Detroit, Michigan;
4Children’s Research Center of Michigan, Children’s Hospital of Michigan,
Michigan; 5Department of Pathology, Wayne State University School of Med-
icine, Detroit, Michigan
Contract grant sponsors: The Ring Screw Textron Chair for Pediatric Cancer
Research, The Georgie Ginopolis Chair for Pediatric Cancer and Hematology.
*Correspondence to: Jeffrey W. Taub, MD, Division of Pediatric Hematology/
Oncology, Children’s Hospital of Michigan, 3901 Beaubien, Detroit, MI
48201-2196. E-mail: jtaub@med.wayne.edu
Received for publication 24 August 2006; Revised 3 April 2007; Accepted 8
May 2007
Am. J. Hematol. 83:34–40, 2008.
Published online 15 August 2007 in Wiley InterScience (www.interscience.
wiley.com).
DOI: 10.1002/ajh.21011
VC 2007 Wiley-Liss, Inc.
American Journal of Hematology 34 http://www3.interscience.wiley.com/cgi-bin/jhome/35105
109 (UPN 35), while the majority of relapses (82%)
occurred at either the end of therapy (n 5 1; UPN 36) or
after therapy completion (n 5 8). The median interval
between therapy completion and relapse was 0.3 years
(range: 42 days to 2.6 years) for the eight off-therapy relap-
ses. Thus, early relapses (occurring within 6 months after
completion of therapy) occurred in eight children, while
three children had late relapses.
Among the 11 patients who relapsed, 3 (27.3%) children
experienced an isolated hematopoietic relapse, while 8
(72.7%) children experienced either isolated extramedullary
(EM) relapses (n 5 6; Testis: 4; CNS: 2) or combined he-
matopoietic and EM relapses (n 5 2; BM 1 CNS: 1; BM1
Testis: 1). Four (UPN 28, 32, 34, and 35) of the five (80%)
children in the hHDALL group who had NCI high-risk crite-
rion (age > 10 years), [11] experienced a relapse. One
teenage patient (UPN 34) who experienced a testicular
relapse, had monosomy 7 and t(1;19)(q23;p13) besides a
high hyperdiploid karyotype (MCN 61-64). Patient (UPN 28)
with a 9p deletion at diagnosis experienced a hematopoi-
etic relapse (MCN 57). Among the 14 (40%) children with
triple trisomies of 14/110/117, only one teenage male
(UPN 35) experienced an on-therapy bone marrow relapse.
The remaining 10 relapses in hHDALL group occurred in
patients who did not have triple trisomies of 14/110/117.
Thus, the presence of triple trisomies of 14/110/117
appeared to be associated with a lower risk of relapse (P <
0.05). There was no significant difference between the fre-
quency of relapses in the hHDALL group between patients
[24% (7/29)] who received repetitive courses of VCR/corti-
costeroid pulses during maintenance compared to patients
[44.4% (4/9)] who did not receive these treatment pulses.
Relapse characteristics of nonhigh hyperdiploid ALL
Among the 97 children in the non-HD ALL group, 57
(58.8%) children qualified for low or standard risk criteria,
while 40 (41.2%) qualified for high risk criteria based on
age at diagnosis, WBC count at diagnosis or presence of
the Philadelphia chromosome. Median age at diagnosis for
the non-hHDALL cohort was 6.5 years (range: 1.5–18
years). Twenty-nine (29.9%; 95% CI 22–38) children experi-
enced a leukemia relapse. Unlike the hHDALL group, the
non-hHDALL group experienced hematopoietic relapses
(62%; n 5 18) more frequently than isolated EM (27.5%;
n 5 8: Testis: 1; CNS: 7) or combined hematopoietic and
EM relapses (10.3%; CNS 1 BM: 3). In the non-hHDALL
group, 82.8% (n 5 24) of the relapses occurred on-therapy,
while 17.2% (n 5 5) of the relapses occurred off-therapy.
The median interval between diagnosis and relapse was
1.6 years (range: 0.28–7.72 years). The median follow-up
for this cohort was 7.4 ± 4.4 years (range: 0.28–15.2 years).
Summary of relapse characteristics and mortality for
the entire cohort
In summary, there was a higher frequency of EM relap-
ses in hHDALL (8/11; 73%) compared with non-hHDALL
patients (11/29; 37.9%) (P 5 0.011). Relative risk of devel-
oping EM relapses in non-HD ALL was 0.27 implying a pro-
tective effect against EM relapses. Caucasian children
were more predisposed to relapse if they had high hyperdi-
TABLE I. Characteristics of Children With Hyperdiploid and Non-Hyperdiploid B-Precursor ALL
Characteristics High hyperdiploidy ALL Non-high hyperdiploidy ALL P value
Total number of patients 38 (28.1%) 97 (71.9%)
Median age at diagnosis (yrs) 3.8 (1.2–16) 6.5 (1.5–18) 0.002
Male: female 22 (58%): 16 (42%) 55 (56.7%): 42 (43.3%) NS
Age >10 yrs 5 (13%) 33 (34%) 0.005
Race: C/AA/O 27 (71%)/6 (16%)/5 (13%) 57 (58.2%)/28 (28.6%)/12 (12.2%)
Median WBC /mm3 count at Dx 8,942 (range: 900–41,700)
Total no of events (relapse 1 death) 11 (28.9%) 33 (34%) NS
Total no of relapse 11 (28.9%) 29 (29.9%) NS
Relapse characteristics
Mean age at relapse (yrs) 6.9 (1.6–16) 9.5 (1.5–18) NS
Male/female 8 (72.7%)/3 (27.3%) 20 (69%)/9 (31%) NS
Age >10 4/11 (36.4%) 14/29 (48.3%) NS
Race: C/AA/O 10 (91%)***/0 (%)/1 (9%) 10 (34.5%)***/14 (48.3%)/5 (17.2%) 0.005
Median follow up (yrs) 8.8 ± 3.9 (0.8–15.2) 7.1 ± 4.4 (0.1–15.2)
Pattern of relapse
Hematopoietic (H) 3 (27%)*** 18 (62.1%)*** 0.053
Total extramedullary relapse 8 (73%)*** 11 (37.1)***
Isolated CNS relapse 0 7
Isolated testis relapse 4 1 0.02|
CNS 1 H 3 2
Testis 1 H 1 1
Mortality 3 (0.07%)**** 26 (26.8%)**** 0.009
Deaths due to relapse 3 (100%)*** 22 (75.9%)*** 0.009¥
Non-relapse deaths 0 7 (24.1 %)
Survival
Event free survival (yrs) 70.5% ± 7.5% 66.4% ± 4.9% NS
Overall survival (yrs) 92.9% ± 4.5% 74.1% ± 4.5% 0.038
NS: not significant.
***: P-value indicates chi-square analysis including hematopoietic versus nonhematopoietic relapses in hyperdiploid and nonhyperdiploid group.
|: P-value indicates v2 analysis between testicular versus all other relapses in hyperdiploid and non-hyperdiploid group.
****: v2 analysis comparing relapses versus no-relapses in hyperdiploid and nonhyperdiploid group.
¥: P-value indicates v2 analysis between deaths due to relapse versus survival after relapses in hyperdiploid and nonhyperdiploid group.
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and FU (yrs) Status
1 O/F 4.6 3,200 56,XX,1X,1X,14,18,19,
110,114,118,118,
121[17]/46,XX [3]
1.2 9904| NA NA 5.0 Alive:CR1
2 C/M 2.8 4,400 56,XY,1X,14,110,114,
114,118,121,122,
12mar[cp12]/46,XY[8]
1.2 9005 NA NA 15.2 Alive:CR1
3 AA/M 3.3 18,400 56,XY,1X,14,16,18,110,
114,117,118,121,
121[15]/46,XY[15]
1.19 9201| NA NA 11.7 Alive:CR1
4 C/M 8.5 2,300 55~57[cp4]/46,XY[23] 1.22 9201| NA NA 8.6 Alive:CR1






1.29 9904| NA NA 4.6 Alive: CR1




1.34 9005 NA NA 14.3 Alive:CR1
7 AA/F 1.3 18,600 5557,XX,1X,14,16,17,
19,114,116,118,121,
121[cp11]/46,XX[9]
1.19 9904| NA NA 5.7 Alive:CR1
8 AA/F 2.9 12,600 5253,XX,dup(1)(q21q32),
16,18,110,114,118,
121,121[cp4]/46,XX[16]
1.29 9904| NA NA 3.6 Alive: on
therapy
9 O/F 3.9 3,500 53,XX,14,16,110,114,117,
121,121[8]/46,XX[12]
1.22 9904| NA NA 4.5 Alive-CR1





1.13 9005 NA NA 14.0 Alive-CR1




1.18 9201| NA NA 7.2 Alive-CR1
12 C/M 3.9 1,500 54,XXcY,14,18,19,114,116,
118,121 [cp6]/46,XY[28]/47,
XXY [18]
1.14 9201| NA NA 12.9 Alive-CR1





1.12 9201| NA NA 10.2 Alive-CR1
14 AA/M 5.0 3,300 5556,XY,1X,14,16,19,110,
114,117,118,121,
121cp7]/46,XY[13]
1.27 9201| NA NA 8.4 Alive-CR1
15 C/M 4.4 2,400 56,XY,1X,14,16,17,110,
114,117,118,121,
121[16]/46,XY[4]
1.17 9201| NA NA 9.2 Alive-CR1




1.18 9005 NA NA 14.8 Alive-CR1
17 C/F 5.4 2,300 55,XX,1X,14,16,110,114,
117,118,add(19)(p13),
121,121[cp7]/46,XX[13]
1.36 9005 NA NA 15.1 Alive-CR1
18 C/M 3.6 6,700 5355,XY,1X,14,16,110,
114,117,118,121,
121[cp18]/46,XY[5]
1.35 9201| NA NA 12.9 Alive-CR1
19 C/M 5.0 5,700 Failed 1.19 9201| NA NA 11.5 Alive-CR1
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ploid cytogenetics (P 5 0.05; Relative risk: 2.17). Male chil-
dren with hHDALL experienced more (5/22; 23%) testicular
relapses compared with the non-hHDALL group (2/55;
3.6%; P 5 0.003; relative risk: 6.30). Additionally, older age
(age > 10 years) at diagnosis of hHDALL was a risk factor
for relapse in both the hHDALL and non-hHDALL groups
(4/5 vs. 14/29; P 5 0.007; relative risk: 1.66). Although the
proportion of relapses appeared higher for hHDALL (11/37)
than non-HD ALL (29/97), the relative risk of relapse was
almost the same for both groups (Relative risk: 0.97).
Overall mortality for the hHDALL and non-hHDALL


















and FU (yrs) Status
20 AA/F 9.1 900 5557,XX,1X,14,16,18,
110,111,114,118,121,
121[cp8]/46,XY[12]
1.23 9904| NA NA 5.6 Alive-CR1
21 C/F 2.87 15000 53,XX,16,19,del(9)(q21q34),
110,114,118,121,
121[17]/46,XX[3]
1.13 9605 NA NA 6.3 Alive-CR1
22 O/F 1.21 21200 56,XX,1X,1X,14,16,110,
114,117,118,121,
121[2] 57,idem,19[4]/46,XX[4]
1.18 9605 NA NA 6.7 Alive-CR1
23 C/F 5.55 6200 52,XX,13,14,16,115,
118,121[5]/46,XX[2]
1.16 9202 NA NA 12.0 Alive-CR1
24 C/F 2.43 13100 54,XX,1X,16,110,114,117,
118,121,121[cp16]/46,XX[6]
1.14 9905 NA NA 4.7 Alive-CR1
25 C/F 4.09 41700 5254,XX,1X,14,16,110,
114,117,121,
121[cp13]/46,XX [12]
1.16 9605 NA NA 5.1 Alive-CR1
26 C/F 2.62 8400 54,XX,1X,1X,14,16,114,117,
118,121[cp26]/46,XX[3]
1.16 9605 NA NA 7.4 Alive-CR1
27 C/M 4.13 11200 5659,XY,1X,1Y,14,16,
19,110,111,114,118,
121,121[cp10]/46,XY[3]
1.14 9905 NA NA 4.7 Alive-CR1
28 C/M 13.6 6,900 57,XY1X,14,18,1del(9)(p21),
110,111,114,118,121,121,
1mar[cp11]/46,XY[9]
1.2 9005 BM 2.4 14 Alive-CR2
29 C/F 2.2 32,000 51,XX,1X,16,114,117,
121[16]/46,XX[4]
1.12 9605| BM On therapy 1.1 Died
30 O/M 3.4 8,500 54,XY,1X,14,16,110,114,114,
121,121[3]/55,idem,117,
del(17)(p11)[6]/46,XY [2]
1.19 9201| BM 1.2 7.3 Alive-CR2,
Post BMT
31 C/M 3.3 8,600 5355,XY,1X,1Y,16,110,
114,117,118,121,
121[cp7]/46,XY[13]
1.31 9405 Testis 0.14 10.5 Alive: CR2,
Post BMT
32 C/M 16.0 2,300 56,XY,1X,14,16,18,110,114,
118,120,121,121[19]/46,XY[1]
1.2 9906| Testis 0.08 2.88 Died
33 C/M 3.2 31,000 54,XY,1X,14,16,114,
117,118,121,121[20]
1.17 9005 Testis End of therapy 14.7 Alive-CR2





1.19 9605| Testis 0.4 8.8 Alive-CR2
35 C/M 15.6 4,300 57,XY,1X,dup(1)(q21q42),14,16,
19,110,114,1dup(14)(q31q32),
117,118,121,121[cp20]
1.21 9005 Testis, BM On therapy 3.9 Died**
36 C/M 1.5 3,500 Failed 1.16 9605| CNS End of therapy 8.8 Alive-CR2
37 C/F 2.6 10,400 55,XY,1X,14,15,16,18,113,
114,118,122[20]
1.20 9605| CNS, BM 1 9.0 Alive- CR2,
Post BMT
38 C/F 4.0 3,500 51,XX,1X,16,114,121,121[25] 1.10 9605| CNS, BM 0.25 8.5 Alive-CR2, OT
Dx: Diagnosis, yrs: years; Int: Interval; C: Caucasian; AA: African American; O: Others; Y: Yes; N: No; NA: Not applicable; H, Hematopoietic (bone
marrow); EM: Extra-medullary; CNS: Central nervous system; CR: Complete Remission; BMT: Bone marrow transplantation.
**: Died after second hematopoietic relapse.
|: Protocols which included repetitive courses of vincrisitne and prednisone/dexamethasone during maintenance phase. All karyotypes were writ-
ten according to the International System for Human Cytogenetics Nomenclature (ISCN) 2005. The gains or losses of chromosomes were
expressed in relation to diploidy. (Reference: ISCN 2005: An International System for Human Cytogenetics Nomenclature. Shaffer L.G. and Tom-
merup N. (eds); S. Karger, Basel 2005.)
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The relapse related mortality was 27.3% (3/11) for the
hHDALL group and 88% (22/29) for the non-hHDALL
group, (P 5 0.007; relative risk: 0.36). Thus hHDALL had
protective effect towards improving survival. An equal pro-
portion of hHDALL (22%; 3/11) and non-hHDALL patients
(22%; 6/27) received stem-cell transplantation as a part of
their salvage therapy. The etiology of nonrelapse related
deaths in five non-hHDALL patients was: gram negative
sepsis (n 5 3), ascending myelitis (n 5 1), Epstein-Barr vi-
rus-related lymphoproliferative disorder in a child with
Down syndrome (n 5 1). The 5-year EFS and OS rates for
the hHDALL group was 70.5 ± 7.5% and 92 ± 4.5%,
respectively, while for the non-hHDALL group, 5-year EFS
and OS were 66.4 ± 4.9% and 74.1 ± 4.5% respectively
(Figs. 1 and 2).
Discussion
Our study identified differences in sites and frequency of
relapses between children with hHDALL and non-hHDALL.
Children with hHDALL had a higher frequency of EM relap-
ses, while children with non-hHDALL had predominantly he-
matopoietic relapses. The majority of relapses in the hHDALL
group occurred at the end of scheduled therapy or after com-
pletion of therapy, while the majority of non-hHDALL relapses
occurred on therapy. Although hHDALL is associated with
favorable prognosis, the proportion of relapses was the same
for both hHDALL (28.9%) and non-hHDALL (29.9%). The sig-
nificant finding was that a higher proportion of hHDALL chil-
dren (8/11) could be salvaged successfully with second line
therapy compared with non-hHDALL (7/29). The 5-year OS
rate for the hHDALL group was (92 ± 4.5)% compared with
(74 ± 4.5)% for the non-hHDALL group, which is comparable
with the literature experience [12,13].
There is limited published literature on the relapse pat-
terns of hHDALL. A study from St. Jude Children’s
Research Hospital reported the outcome of 182 children
with hHDALL (51–67 chromosomes) treated on several dif-
ferent protocols [10]. Twenty-nine (16%) patients relapsed
(bone marrow: 20; CNS: 6; testicle: 2; EM: 1), while an addi-
tional nine (5%) patients developed either secondary AML/
MDS, had induction failures or died in remission. A report
by the Children’s Cancer Group 1900 series ALL studies
suggested that relapses in patients with triple trisomies
were primarily EM [14]. The Medical Research Council
(MRC) United Kingdom Acute Lymphoblastic Leukemia XI
(UKALL) group reported the outcome of 807 children with
hHDALL, though did not elaborate on the relapse character-
istics [13]. The 5-year OS for this cohort was 91% (95% CI,
88–93%). A recent review of the BFM (Berlin-Frankfurt-
Muenster) ALL studies also identified that the majority of
relapses occurred in good risk patients [15]. The present
study has shown that hHDALL had a trend towards EM
relapses (P 5 0.053) compared with non-hHDALL. How-
ever, this analysis is limited by a large difference in sample
size between two groups and selection bias towards non-
HD group, as children who did not have high hyperdiploid
cytogenetics formed the non-HD group. Limited sample size
of hHDALL group has further limited the ability to do mean-
ingful statistical analysis. Above all, the prognostic role of
TEL/AML1 translocation on hHDALL outcome was not
examined, as the diagnostic screening for this translocation
had only been performed in the more recent era of POG
studies and not in earlier studies. Since a large proportion
of the patients from the current study were diagnosed and
enrolled on earlier POG studies, the present study did not
have ability to evaluate if TEL/AML1 protects against
adverse outcome.
Male sex and older age were associated with an adverse
outcome in the current study, while triple trisomies of 14/
110/117 was protective against relapse. The influence of
older age and gender as a predictor of poor outcome has
been reported already in the MRC UKALL XI study [13].
This study has shown that children younger than age 10
years with both 14 and 110 had an improved survival
compared with those older than 10 years with both 14 and
110 (96% vs. 84% at 5 years, P < 0.0001) [15]. These
findings imply that male gender and older (> 10 years) chil-
dren might benefit from more intensive chemotherapy regi-
mens as currently used in frontline COG ALL protocols
while young children with triple trisomy of 14,110,117 can
be treated with low intensity chemotherapy regimens. The
salvage therapy used in relapsed cases was similar
between hHDALL and non-hHDALL cases, including the
proportion of patients who underwent allogeneic bone mar-
row transplant in our study. Despite this, the OS was signifi-
cantly higher in the hHDALL compared with non-hHDALL
cases due to a high successful salvage rate in hHDALL
cases. This finding may suggest that the mechanism of
Figure 1. Event free survival for high hyperdiploid and
non-high hyperdiploid ALL.
Figure 2. Overall survival for high hyperdiploid and non-
high hyperdiploid ALL.
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relapse in hHDALL cases may not entirely be related to
drug resistance.
Since hyperdiploid blasts are sensitive to cell cycle spe-
cific drugs and antimetabolites viz. methotrexate and 6-MP
[16–18], the relationship between anti-metabolite dose in-
tensity/therapy adherence and relapse was analyzed.
Although the chemotherapy protocols have changed over
the decade, there was no difference in cumulative antimeta-
bolite treatment intensity and treatment interruptions
between hHDALL patients who relapsed and those who
remained in first complete remission [data not shown], fur-
ther supporting the hypothesis that the relapse mecha-
nisms in hHDALL maybe unrelated to anti-metabolite drug
resistance in the majority of cases.
It is interesting to note that earlier studies during an era
of evolution of ALL therapy from our own institution reported
a lower incidence of testicular relapse [19]. The important
component of leukemia therapy in these legacy studies
included a repetitive reinduction strategy with VCR/ PDN
along with oral 6-MP and methotrexate every 10 weeks over
5 years [19]. An early study from St. Jude Children’s
Research Hospital, showed a lower incidence of testicular
relapse in regimens that included frequent VCR/PDN pulses
[20]. A recent report from Children’s Cancer Study Group
(CCSG) further underscores the importance of repetitive
courses of VCR/PDN for maintaining durable remissions
[21]. In the CCG-161 study, 631 children with ALL at low
risk for relapse were randomized to receive monthly pulses
of VCR/PDN during maintenance therapy in addition to
standard therapy with 6-MP and methotrexate, and either
cranial irradiation during consolidation or intrathecal metho-
trexate every 3 months during maintenance. This study
showed a superior 5-year relapse-free survival for the chil-
dren who were randomized to receive VCR/PDN irrespec-
tive of randomization to cranial irradiation during consolida-
tion (76.7% vs. 63.9%; P 5 0.002). The important reason
for the difference in relapse-free survival was primarily due
to less bone marrow relapses (P 5 0.0008), and in boys,
due to fewer testicular relapses (P 5 0.003). These obser-
vations may imply that repetitive courses of VCR/PDN may
be protective against both hematopoietic and testicular
relapse. In contrast, several standard/low risk POG proto-
cols did not incorporate VCR/PDN pulses during mainte-
nance therapy, which may have contributed to the higher
EM relapses observed in our study. In the present study,
relapse free survival was not statistically different between
those who received VCR/PDN pulses versus those who did
not. However, it is interesting to note that among five chil-
dren who had testicular involvement at relapse, three (60%)
did not receive VCR/PDN pulses during maintenance ther-
apy (Table II). This finding may support the potential benefit
of this treatment strategy in preventing testicular relapse in
hHDALL. Hence, based on the literature experience, the
protective efficacy of VCR/PDN pulses in preventing testicu-
lar relapse needs further exploration in clinical and pharma-
cologic studies in children with hHDALL.
Our study suggests that the biology of high hyperdiploid
and non-high hyperdiploid lymphoblasts is different.
Although the majority of hHDALL blast cells are in S-phase,
paradoxically they have greater propensity to undergo apo-
ptosis [22]. Since chemotherapy medications achieve
higher concentrations in the bone marrow, blast cell popula-
tions in the bone marrow can potentially be eradicated.
However, blast cells localized in EM sites like testis or CNS
may not be eradicated easily as chemotherapy drugs can-
not achieve adequate cytotoxic concentrations due to the
so called ‘‘blood-brain barrier’’ or ‘‘blood-testicular barrier.’’
In addition, it has been shown that intra-testicular biochemi-
cal regulation is known to be capable of decreasing the
proliferation of leukemic cells [23]. Since most of the cyto-
toxic drugs used in the treatment of ALL have a poor effect
on nondividing cells, these nondividing ‘‘hidden’’ leukemia
cells may not be eliminated by chemotherapy. The blast
cells at sanctuary sites retain their ability of uncontrolled
proliferation to produce locally invasive disease once they
escape immune surveillance mechanisms. As the majority
of EM relapses occurred within 6 months of completion of
therapy and 80% of those children responded to second
line therapy, this may indicate that the original leukemia
cells were transiently suppressed at EM sites without alter-
ing the primary biology of the disease.
The fundamental question is, why there are differences
in relapses at sanctuary sites between hHDALL and non-
hHDALL cases. One potential mechanism could be related
to the role of chemokines especially stromal cell-derived
factor-1 (SDF-1) and tissue specific expression of its recep-
tor CXCR4 and its influence on lymphoblast trafficking [24].
SDF1 plays an important role in hematopoiesis, develop-
ment, and organization of the immune system [25]. There
is evidence that CXCR4 receptors are uniformly expressed
at high density on all B-precursor lymphoblasts and bone
marrow stromal cells, explaining bone marrow involvement
in ALL [24–26]. Recent animal studies have shown that
these receptors are also expressed in the testis and the
CNS [27,28]. Liu et al. have shown the increased expres-
sion of CXCR4 receptors on leukemia blasts with EM relap-
ses [29]. Hence, further clarification on CXCR4 expression
on hHDALL blasts may shed more light in predicting EM
relapses in hHDALL.
In conclusion, biological differences exist between
relapse patterns of hHDALL and non-hHDALL cases
related to relapse sites and time periods when relapses
occur. Despite relapses, hHDALL continues to be respon-
sive to second line therapy with high overall survival rates.
Patients and Methods
Patient selection
All consecutive children greater than 1 year of age with newly diag-
nosed B-precursor ALL at CHM from January 1991 to December 2002
were included in this retrospective cohort study. The diagnosis of ALL
was based on standard morphological, cytochemical, and immunophe-
notype criteria. The DI was determined by flow-cytometry as the ratio
of DNA content in leukemic cells G0/G1 cells versus normal G0/G1
lymphocytes. Karyotype and immunophenotype analysis of leukemic
cells was performed at our institution, while the DI was analyzed in the
Pediatric Oncology Group/Children’s Oncology Group ALL Biology Ref-
erence Laboratory. Children whose karyotype revealed a MCN of 51–
65 were included in the hHDALL group, while all the remaining children
without a high hyperdiploid karyotype were included in the non-hHDALL
group. This retrospective review was approved by the Wayne State Uni-
versity Human Investigation Committee.
Treatment details
All children were enrolled on Pediatric Oncology Group (POG) proto-
cols and were classified as low-risk, standard-risk, and high-risk for
ALL based on their age at diagnosis, WBC count at diagnosis, and leu-
kemia cytogenetic subgroups as outlined by cooperative group protocol
criteria according to the treatment era they were being treated in. The
low-risk protocols included POG 9201, 9005, and 9904, the standard-
risk protocols included POG 9202, 9405, 9605, and 9905 and the
high-risk protocols included 9006, 9203, 9406, and 9906. Concise infor-
mation of these protocols have been published earlier [30] and detail
information is available at http://www.acor.org/ped-onc/diseases/ALL.
All hHDALL patients in this study were treated with either low-risk or
standard-risk protocols except for two teenage patients who received
induction with high-risk protocol. All treatment schedules included a
phase of induction (weeks 1 to 4), consolidation phase (weeks 5 to 24/
33) and maintenance phase (weeks 25/34-130). In general, three-drug
induction therapy (vincristine, L-asparaginase, and prednisone [PDN]/or
dexamethasone) was used for the low or standard risk patients. Two
teenage patients in the hHDALL group received induction therapy
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which also included daunorubicin according to the high-risk protocol
based on their age (>10 years) at diagnosis and were subsequently
treated on standard-risk protocols for consolidation and maintenance
therapy. Central nervous system (CNS) directed therapy included intra-
venous methotrexate (1–2.5 g/m2), with intrathecal methotrexate or tri-
ple therapy. All treatment protocols incorporated maintenance therapy
with daily 6-mercaptopurine (6-MP) and weekly methotrexate (oral or
intramuscular), intrathecal chemotherapy and vincristine (VCR)/cortico-
steroid pulses every 8–16 weeks except for the POG 9005 and 9405
protocols.
Statistical analysis
The primary end point of the study was event free survival (EFS). An
‘‘event’’ was defined as induction failure, death due to any etiology (e.g.,
infection) or disease relapse at any site. The EFS was calculated from
the date of diagnosis to the date of first event or last follow-up which-
ever occurred first. Overall survival (OS) was defined as time interval
between date of diagnosis to the last follow up. Kaplan–Meier life tables
and survival curves were constructed using the log-rank method [31].
The log-rank test was used to test the independent influence of the fol-
lowing variables on the EFS: sex, race, and immunophenotype. Pat-
terns of relapse in hHDALL were compared with non-hHDALL children
diagnosed during the same period. To assess the differences between
the groups, v2 or Fisher’s exact test was used for the categorical data
and t-tests were used for continuous data. A P value < 0.05 was con-
sidered significant to confirm the association between variables. Analy-
ses were performed using SPSS version 13 statistical software.
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